vs
Side-by-side financial comparison of Magyar Bancorp, Inc. (MGYR) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $8.9M, roughly 1.4× Magyar Bancorp, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 35.4%, a 215.3% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 19.0%).
Magyar Bank is a bank based in New Brunswick, New Jersey with branches in Central Jersey.
MGYR vs SPRO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.9M | $12.6M |
| Net Profit | $3.1M | $31.5M |
| Gross Margin | — | — |
| Operating Margin | 48.3% | — |
| Net Margin | 35.4% | 250.7% |
| Revenue YoY | 19.0% | 24080.8% |
| Net Profit YoY | 50.4% | 250.9% |
| EPS (diluted) | $0.50 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.9M | $12.6M | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $12.0K | ||
| Q4 24 | — | $52.0K | ||
| Q3 24 | — | $65.0K | ||
| Q2 24 | $7.2M | $114.0K | ||
| Q1 24 | $7.5M | $140.0K |
| Q4 25 | $3.1M | $31.5M | ||
| Q3 25 | — | $-7.4M | ||
| Q2 25 | — | $-1.7M | ||
| Q1 25 | — | $-13.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-17.1M | ||
| Q2 24 | $1.7M | $-17.9M | ||
| Q1 24 | $1.9M | $-12.7M |
| Q4 25 | 48.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -122758.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -28604.6% | ||
| Q2 24 | 30.5% | -16720.2% | ||
| Q1 24 | 32.1% | -9987.1% |
| Q4 25 | 35.4% | 250.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -115550.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -26380.0% | ||
| Q2 24 | 23.5% | -15668.4% | ||
| Q1 24 | 25.1% | -9049.3% |
| Q4 25 | $0.50 | $0.56 | ||
| Q3 25 | — | $-0.13 | ||
| Q2 25 | — | $-0.03 | ||
| Q1 25 | — | $-0.25 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.32 | ||
| Q2 24 | $0.27 | $-0.33 | ||
| Q1 24 | $0.30 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.1M | $40.3M |
| Total DebtLower is stronger | $49.1M | — |
| Stockholders' EquityBook value | $121.7M | $59.0M |
| Total Assets | $1.0B | $68.9M |
| Debt / EquityLower = less leverage | 0.40× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.1M | $40.3M | ||
| Q3 25 | — | $48.6M | ||
| Q2 25 | — | $31.2M | ||
| Q1 25 | — | $48.9M | ||
| Q4 24 | — | $52.9M | ||
| Q3 24 | — | $76.3M | ||
| Q2 24 | $49.0M | $63.5M | ||
| Q1 24 | $50.0M | $82.3M |
| Q4 25 | $49.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $121.7M | $59.0M | ||
| Q3 25 | — | $26.5M | ||
| Q2 25 | — | $32.8M | ||
| Q1 25 | — | $33.8M | ||
| Q4 24 | — | $46.1M | ||
| Q3 24 | — | $65.5M | ||
| Q2 24 | $109.0M | $80.5M | ||
| Q1 24 | $107.6M | $96.2M |
| Q4 25 | $1.0B | $68.9M | ||
| Q3 25 | — | $54.2M | ||
| Q2 25 | — | $62.1M | ||
| Q1 25 | — | $77.7M | ||
| Q4 24 | — | $110.5M | ||
| Q3 24 | — | $135.2M | ||
| Q2 24 | $944.4M | $149.9M | ||
| Q1 24 | $928.6M | $167.7M |
| Q4 25 | 0.40× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.7M | $-8.4M |
| Free Cash FlowOCF − Capex | $3.7M | — |
| FCF MarginFCF / Revenue | 41.4% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.17× | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | $8.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.7M | $-8.4M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | — | $-17.7M | ||
| Q1 25 | — | $-4.0M | ||
| Q4 24 | — | $-23.4M | ||
| Q3 24 | — | $12.8M | ||
| Q2 24 | $1.7M | $-18.7M | ||
| Q1 24 | $553.0K | $5.9M |
| Q4 25 | $3.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $428.0K | — |
| Q4 25 | 41.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.5% | — | ||
| Q1 24 | 5.7% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | 1.17× | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
